Ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
continuous	continuous	O	O	O	O
infusion	infusion	O	O	O	O
without	without	O	O	O	O
mesna	mesna	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
phase	phase	O	O	O	O
I	i	O	O	O	O
trial	trial	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
14-day	14-day	O	O	O	O
cycle	cycle	O	O	O	O
.	.	O	O	O	O

Twenty	twenty	O	O	O	O
patients	patients	O	O	O	O
received	received	O	O	O	O
27	27	O	O	O	O
courses	courses	O	O	O	O
of	of	O	O	O	O
ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
administered	administered	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
24-hour	24-hour	O	O	O	O
continuous	continuous	O	O	O	O
infusion	infusion	O	O	O	O
for	for	O	O	O	O
14	14	O	O	O	O
days	days	O	O	O	O
without	without	O	O	O	O
Mesna	mesna	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
goal	goal	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
to	to	O	O	O	O
deliver	deliver	O	O	O	O
a	a	O	O	O	O
dose	dose	O	O	O	O
rate	rate	O	O	O	O
and	and	O	O	O	O
total	total	O	O	O	O
cumulative	cumulative	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
that	that	O	O	O	O
would	would	O	O	O	O
be	be	O	O	O	O
comparable	comparable	O	O	O	O
to	to	O	O	O	O
standard	standard	O	O	O	O
bolus	bolus	O	O	O	O
or	or	O	O	O	O
short-term	short-term	O	O	O	O
infusions	infusions	O	O	O	O
administered	administered	O	O	O	O
with	with	O	O	O	O
Mesna	mesna	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Dose	dose	O	O	O	O
escalations	escalations	O	O	O	O
proceeded	proceeded	O	O	O	O
from	from	O	O	O	O
200	200	O	O	O	O
to	to	O	O	O	O
300	300	O	O	O	O
,	,	O	O	O	O
400	400	O	O	O	O
,	,	O	O	O	O
450	450	O	O	O	O
,	,	O	O	O	O
500	500	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
550	550	O	O	O	O
mg/m2/d	mg/m2/d	O	O	O	O
.	.	O	O	O	O

Four	four	O	O	O	O
patients	patients	O	O	O	O
developed	developed	O	O	O	O
transient	transient	O	O	O	O
microscopic	microscopic	O	O	O	O
hematuria	hematuria	O	DISEASE	OTHERS	I
at	at	O	O	O	O
400	400	O	O	O	O
,	,	O	O	O	O
450	450	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
500	500	O	O	O	O
mg/m2/d	mg/m2/d	O	O	O	O
.	.	O	O	O	O

There	there	O	O	O	O
were	were	O	O	O	O
no	no	O	O	O	O
instances	instances	O	O	O	O
of	of	O	O	O	O
macroscopic	macroscopic	O	O	O	O
hematuria	hematuria	O	DISEASE	OTHERS	I
.	.	O	O	O	O

At	at	O	O	O	O
550	550	O	O	O	O
mg/m2/d	mg/m2/d	O	O	O	O
,	,	O	O	O	O
three	three	O	O	O	O
patients	patients	O	O	O	O
experienced	experienced	O	O	O	O
nonurologic	nonurologic	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
;	;	O	O	O	O
confusion	confusion	O	DISEASE	OTHERS	I
(	(	O	O	O	O
1	1	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
nausea	nausea	O	DISEASE	OTHERS	I
(	(	O	O	O	O
1	1	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
Grade	grade	O	O	O	O
2	2	O	O	O	O
leukopenia	leukopenia	O	DISEASE	OTHERS	I
(	(	O	O	O	O
1	1	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
recommended	recommended	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
500	500	O	O	O	O
mg/m2/d	mg/m2/d	O	O	O	O
delivers	delivers	O	O	O	O
a	a	O	O	O	O
total	total	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
7	7	O	O	O	O
g/m2	g/m2	O	O	O	O
per	per	O	O	O	O
cycle	cycle	O	O	O	O
,	,	O	O	O	O
which	which	O	O	O	O
is	is	O	O	O	O
comparable	comparable	O	O	O	O
to	to	O	O	O	O
that	that	O	O	O	O
delivered	delivered	O	O	O	O
in	in	O	O	O	O
clinical	clinical	O	O	O	O
practice	practice	O	O	O	O
for	for	O	O	O	O
bolus	bolus	O	O	O	O
or	or	O	O	O	O
short-term	short-term	O	O	O	O
infusion	infusion	O	O	O	O
.	.	O	O	O	O

Because	because	O	O	O	O
few	few	O	O	O	O
patients	patients	O	O	O	O
received	received	O	O	O	O
multiple	multiple	O	O	O	O
courses	courses	O	O	O	O
over	over	O	O	O	O
time	time	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
cumulative	cumulative	O	O	O	O
effects	effects	O	O	O	O
are	are	O	O	O	O
indeterminate	indeterminate	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
present	present	O	O	O	O
trial	trial	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
frequency	frequency	O	O	O	O
and	and	O	O	O	O
predictability	predictability	O	O	O	O
of	of	O	O	O	O
hematuria	hematuria	O	DISEASE	OTHERS	I
are	are	O	O	O	O
not	not	O	O	O	O
precise	precise	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
at	at	O	O	O	O
least	least	O	O	O	O
daily	daily	O	O	O	O
monitoring	monitoring	O	O	O	O
by	by	O	O	O	O
urine	urine	O	O	O	O
Hematest	hematest	O	O	O	O
is	is	O	O	O	O
essential	essential	O	O	O	O
,	,	O	O	O	O
adding	adding	O	O	O	O
Mesna	mesna	CHEMICALS	O	OTHERS	I
to	to	O	O	O	O
the	the	O	O	O	O
infusate	infusate	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
persistent	persistent	O	O	O	O
hematuria	hematuria	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
protracted	protracted	O	O	O	O
infusion	infusion	O	O	O	O
schedule	schedule	O	O	O	O
for	for	O	O	O	O
ifosfamide	ifosfamide	CHEMICALS	O	OTHERS	I
permits	permits	O	O	O	O
convenient	convenient	O	O	O	O
outpatient	outpatient	O	O	O	O
administration	administration	O	O	O	O
without	without	O	O	O	O
Mesna	mesna	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
reduces	reduces	O	O	O	O
the	the	O	O	O	O
drug	drug	O	O	O	O
cost	cost	O	O	O	O
of	of	O	O	O	O
clinical	clinical	O	O	O	O
usage	usage	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
agent	agent	O	O	O	O
by	by	O	O	O	O
up	up	O	O	O	O
to	to	O	O	O	O
 	 	O	O	O	O
890	890	O	O	O	O
per	per	O	O	O	O
cycle	cycle	O	O	O	O
.	.	O	O	O	O

Clinical	clinical	O	O	O	O
activity	activity	O	O	O	O
was	was	O	O	O	O
demonstrated	demonstrated	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
single	single	O	O	O	O
patient	patient	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
a	a	O	O	O	O
comparative	comparative	O	O	O	O
trial	trial	O	O	O	O
of	of	O	O	O	O
standard	standard	O	O	O	O
bolus	bolus	O	O	O	O
schedules	schedules	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
protracted	protracted	O	O	O	O
infusion	infusion	O	O	O	O
schedule	schedule	O	O	O	O
will	will	O	O	O	O
be	be	O	O	O	O
necessary	necessary	O	O	O	O
to	to	O	O	O	O
determine	determine	O	O	O	O
if	if	O	O	O	O
the	the	O	O	O	O
clinical	clinical	O	O	O	O
effectiveness	effectiveness	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
drug	drug	O	O	O	O
is	is	O	O	O	O
maintained	maintained	O	O	O	O
.	.	O	O	O	O

